CD79A and COVID-19: Antibody class‐switching to IgA seems to be particularly dependent on the clinical picture, with more severe COVID‐19 cases developing higher titers to protect mucosal surfaces, such as in the gastrointestinal and upper respiratory tracts [50, 62], while asymptomatic/mild cases with less disseminated pathology do not always engender detectable anti‐viral IgA in peripheral circulation.